For full functionality, including active links, we recommend downloading the PDF. Certain interactive features may not operate within the embedded viewer.
Download this PDF file

 

Crossref Citations

1. Simplified antiretroviral treatment regimens: the dolutegravir revolution
MM Makiwane, KC Mothata-Motswaledi, E Osuch
South African General Practitioner  vol: 5  issue: 1  first page: 8  year: 2024  
doi: 10.36303/SAGP.0276

2. Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV
Eric S. Daar, Chloe Orkin, Paul E. Sax, Debbie Hagins, Anton Pozniak, Kimberly Workowski, Cynthia Brinson, Juan Manuel Tiraboschi, Hui Liu, Chris Deaton, Cal Cohen, Sharline Madera, Jason T. Hindman, Moti Ramgopal
AIDS Research and Therapy  vol: 22  issue: 1  year: 2025  
doi: 10.1186/s12981-025-00732-w

3. Association between transitioning to a dolutegravir-based regimen and risk of incident hypertension in adults with HIV in West Africa: a multicentre target trial emulation study
Romain Millot, Thierry Tiendrebeogo, Oliver Ezechi, Armel Poda, Albert Minga, Karen Malateste, Igho Ofotokun, Didier K. Ekouevi, Antoine Jaquet
eClinicalMedicine  vol: 90  first page: 103584  year: 2025  
doi: 10.1016/j.eclinm.2025.103584

4. Assessment of weight gain in adult patients living with HIV receiving first‐line dolutegravir‐based or efavirenz‐based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study
Shobna Sawry, Kassahun Ayalew, Gloria Maimela, Melissa Briggs‐Hagen, Marelize van Wyk‐Heath, Simangele Mthethwa, Sannie Shai, Nkululeko N. Mngomezulu, Lawrence Tlhowe, Josephine Achere‐Darko, Jason Bedford, Catherine E. Martin, Lee Fairlie, John Imrie
HIV Medicine  vol: 25  issue: 7  first page: 826  year: 2024  
doi: 10.1111/hiv.13638

5. More pressure on integrase strand-transfer inhibitors?
Anton L Pozniak, W D Francois Venter
The Lancet HIV  vol: 11  issue: 5  first page: e278  year: 2024  
doi: 10.1016/S2352-3018(24)00015-8

6. DORA: 48‐week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir‐ or efavirenz‐ to doravirine‐based first‐line antiretroviral therapy
Joana Woods, Simiso Sokhela, Godspower Akpomiemie, Bronwyn Bosch, Karlien Möller, Esther Bhaskar, Chelsea Kruger, Ncomeka Manentsa, Noxolo Tom, Philadelphia Macholo, Nomathemba Chandiwana, Andrew Hill, Michelle Moorhouse, Willem D. F. Venter
HIV Medicine  vol: 26  issue: 1  first page: 81  year: 2025  
doi: 10.1111/hiv.13711

7. Effect of weight gain on blood pressure in Ugandan persons with HIV on dolutegravir/lamivudine/ tenofovir disoproxil fumarate over 48 weeks
Willington Amutuhaire, Barbara Castelnuovo, Nele Brusselaers, Martin Nabwana, Lal Muhammad, Brendan Maloney, Bridgette Nixon, Jean-Marc Schwarz, Frank Mulindwa, Sarah Nanzigu
PLOS One  vol: 20  issue: 6  first page: e0325020  year: 2025  
doi: 10.1371/journal.pone.0325020

8. Prevalence and risk factors of adverse drug events with dolutegravir-based regimens among Thai people living with HIV: a retrospective cohort study
Sutthipun Suriya, Siriyaporn Wanitchakorn
AIDS Research and Therapy  vol: 22  issue: 1  year: 2025  
doi: 10.1186/s12981-025-00817-6

9. Low CD4 counts predict excessive weight gains during first-line treatment for HIV
Andrew Hill, Tamara Tovar Sanchez, Eric Delaporte, Simiso Sokhela, Bryony Simmons, Charles Kouanfack, Kaitlyn Mccann, Jacob Levi, Cassandra Fairhead, Francois Venter
Journal of Antimicrobial Chemotherapy  vol: 79  issue: 9  first page: 2369  year: 2024  
doi: 10.1093/jac/dkae238

10. Impact of switching to a dolutegravir‐based regimen on body weight changes: insights from West African adult HIV cohorts
Thierry Tiendrebeogo, Karen Malateste, Armel Poda, Albert Minga, Cecile D. Lahiri, Oliver Ezechi, Didier K. Ekouevi, Igho Ofotokun, Antoine Jaquet
Journal of the International AIDS Society  vol: 27  issue: 12  year: 2024  
doi: 10.1002/jia2.26371